Condition

Steroid-Induced Diabetes

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting1

Common interventions5

Lead sponsors shown3

Clinical trials

4 shown

The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced DiabetesNCT06318442 · 2024-05-15

RECRUITING

Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced DiabetesNCT07117240 · 2025-07-10

ENROLLING_BY_INVITATION

Predictive Factors and Monitoring Strategies in Steroid-Induced DiabetesNCT07190378 · 2025-06-20

ENROLLING_BY_INVITATION

Adherence in Global Airways - Steroid Intake and Effects on Chronic RhinosinosinutisNCT05843019 · 2023-04-12

UNKNOWN

Common interventions

Intensive insulin therapyDRUG1 lixisenatide + glargineDRUG1 Metformin Oral TabletDRUG1 PlaceboDRUG1 Semaglutide Oral ProductDRUG1

Leading sponsors

Medical University of Warsaw 2 Christiane Haase 1 Imperial College London 1

Trial status mix

ENROLLING_BY_INVITATION2

RECRUITING1

UNKNOWN1

Phase mix

NA1

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.